REPLIGEN CORP Revenue from Contract with Customer, Including Assessed Tax
REPLIGEN CORP (RGEN) reported Revenue from Contract with Customer, Including Assessed Tax of $204.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-07-29
- REPLIGEN CORP revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $204.13M, a 11.93% increase year-over-year.
- REPLIGEN CORP revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $194.25M, a 14.83% increase year-over-year.
- REPLIGEN CORP revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $197.91M, a 18.12% increase year-over-year.
- REPLIGEN CORP revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $188.81M, a 21.91% increase year-over-year.
- REPLIGEN CORP revenue from contract with customer, including assessed tax for fiscal 2025 was $738.26M, a 16.36% increase from fiscal 2024.
- REPLIGEN CORP revenue from contract with customer, including assessed tax for fiscal 2024 was $634.44M, a 0.33% increase from fiscal 2023.
- REPLIGEN CORP revenue from contract with customer, including assessed tax for fiscal 2023 was $632.36M, a 21.11% decline from fiscal 2022.
- REPLIGEN CORP revenue from contract with customer, including assessed tax for fiscal 2022 was $801.54M, a 19.54% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 12 month | Revenue from Contract with Customer, Including Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $204.13M 10-Q · filed 2026-07-29 | $398.38M 10-Q · filed 2026-07-29 | $596.30M derived: sum of 3 quarters · filed 2026-07-29 | $785.10M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $194.25M 10-Q · filed 2026-05-06 | $392.17M derived: sum of 2 quarters · filed 2026-05-06 | $580.97M derived: sum of 3 quarters · filed 2026-05-06 | $763.34M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $197.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $386.72M derived: sum of 2 quarters · filed 2026-02-26 | $569.08M derived: sum of 3 quarters · filed 2026-07-29 | $738.26M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $188.81M 10-Q · filed 2025-11-04 | $371.17M derived: sum of 2 quarters · filed 2026-07-29 | $540.34M 10-Q · filed 2025-11-04 | $707.89M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $182.37M 10-Q · filed 2026-07-29 | $351.54M 10-Q · filed 2026-07-29 | $519.09M derived: sum of 3 quarters · filed 2026-07-29 | $673.96M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $169.17M 10-Q · filed 2026-05-06 | $336.72M derived: sum of 2 quarters · filed 2026-05-06 | $491.59M derived: sum of 3 quarters · filed 2026-05-06 | $650.43M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $167.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $322.42M derived: sum of 2 quarters · filed 2026-02-26 | $481.26M derived: sum of 3 quarters · filed 2026-02-26 | $634.44M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $154.87M 10-Q · filed 2025-11-04 | $313.71M derived: sum of 2 quarters · filed 2025-11-04 | $466.89M 10-Q · filed 2025-11-04 | $633.51M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $158.84M 10-Q · filed 2025-08-07 | $154.07M 10-Q · filed 2024-07-30 | $312.02M 10-Q · filed 2025-08-07 | $305.42M 10-Q · filed 2024-07-30 | $478.64M derived: sum of 3 quarters · filed 2026-02-26 | $619.83M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $153.18M 10-Q · filed 2025-04-29 | $151.35M 10-Q · filed 2024-05-01 | $319.80M derived: sum of 2 quarters · filed 2026-02-26 | $461.00M derived: sum of 3 quarters · filed 2026-02-26 | $620.16M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $166.62M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $307.81M derived: sum of 2 quarters · filed 2026-02-26 | $466.98M derived: sum of 3 quarters · filed 2026-02-26 | $632.36M 10-K · filed 2026-02-26 | $638.76M 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $141.19M 10-Q/A · filed 2024-11-18 | $300.36M derived: sum of 2 quarters · filed 2024-11-18 | $465.74M 10-Q/A · filed 2024-11-18 | $483.02M 10-Q · filed 2023-10-31 | $652.50M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-06-30 | $159.17M 10-Q/A · filed 2024-11-18 | $324.55M 10-Q/A · filed 2024-11-18 | $341.83M 10-Q · filed 2023-08-02 | $511.31M derived: sum of 3 quarters · filed 2025-03-14 | $712.05M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-03-31 | $165.38M 10-Q/A · filed 2024-11-18 | $182.66M 10-Q · filed 2023-05-02 | $352.14M derived: sum of 2 quarters · filed 2025-03-14 | $552.88M derived: sum of 3 quarters · filed 2025-03-14 | $760.52M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2022-12-31 | $186.76M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $387.50M derived: sum of 2 quarters · filed 2025-03-14 | $595.14M derived: sum of 3 quarters · filed 2025-03-14 | $801.54M 10-K · filed 2025-03-14 | ||||
| 2022-09-30 | $200.74M 10-Q/A · filed 2024-11-18 | $408.37M derived: sum of 2 quarters · filed 2024-11-18 | $614.77M 10-Q/A · filed 2024-11-18 | $801.29M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-06-30 | $207.63M 10-Q/A · filed 2024-11-18 | $414.03M 10-Q/A · filed 2024-11-18 | $600.55M derived: sum of 3 quarters · filed 2024-11-18 | $778.77M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-03-31 | $206.40M 10-Q/A · filed 2024-11-18 | $392.92M derived: sum of 2 quarters · filed 2024-11-18 | $571.14M derived: sum of 3 quarters · filed 2024-11-18 | $734.10M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2021-12-31 | $186.52M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $364.74M derived: sum of 2 quarters · filed 2024-11-18 | $527.70M derived: sum of 3 quarters · filed 2024-11-18 | $670.53M 10-K/A · filed 2024-11-18 | ||||
| 2021-09-30 | $178.22M 10-Q · filed 2022-11-01 | $341.18M derived: sum of 2 quarters · filed 2022-11-01 | $484.01M 10-Q · filed 2022-11-01 | $592.66M derived: sum of 4 quarters · filed 2022-11-01 | ||||
| 2021-06-30 | $162.96M 10-Q · filed 2022-08-02 | $305.80M 10-Q · filed 2022-08-02 | $414.44M derived: sum of 3 quarters · filed 2022-08-02 | $508.50M derived: sum of 4 quarters · filed 2022-08-02 | ||||
| 2021-03-31 | $142.84M 10-Q · filed 2022-04-27 | $251.49M derived: sum of 2 quarters · filed 2022-04-27 | $345.55M derived: sum of 3 quarters · filed 2022-04-27 | $433.01M derived: sum of 4 quarters · filed 2022-04-27 | ||||
| 2020-12-31 | $108.65M 10-K · filed 2021-02-24 | $202.71M derived: sum of 2 quarters · filed 2021-10-28 | $290.17M derived: sum of 3 quarters · filed 2021-10-28 | $366.26M 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | $94.06M 10-Q · filed 2021-10-28 | $181.52M derived: sum of 2 quarters · filed 2021-10-28 | $257.61M 10-Q · filed 2021-10-28 | $327.09M derived: sum of 4 quarters · filed 2021-10-28 | ||||
| 2020-06-30 | $87.46M 10-Q · filed 2021-07-27 | $163.55M 10-Q · filed 2021-07-27 | $233.03M derived: sum of 3 quarters · filed 2021-07-27 | $302.47M derived: sum of 4 quarters · filed 2021-07-27 | ||||
| 2020-03-31 | $76.09M 10-Q · filed 2021-05-04 | $145.56M derived: sum of 2 quarters · filed 2021-05-04 | $215.01M derived: sum of 3 quarters · filed 2021-05-04 | $285.70M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | $69.47M 10-K · filed 2021-02-24 | $138.92M derived: sum of 2 quarters · filed 2021-02-24 | $209.61M derived: sum of 3 quarters · filed 2021-02-24 | $270.25M 10-K · filed 2022-02-17 | ||||
| 2019-09-30 | $69.44M 10-K · filed 2021-02-24 | $140.14M derived: sum of 2 quarters · filed 2021-02-24 | $200.77M 10-Q · filed 2020-11-05 | $252.71M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $70.69M 10-K · filed 2021-02-24 | $131.33M 10-Q · filed 2020-07-30 | $183.27M derived: sum of 3 quarters · filed 2021-02-24 | $232.80M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $60.63M 10-K · filed 2021-02-24 | $112.58M derived: sum of 2 quarters · filed 2021-02-24 | $162.10M derived: sum of 3 quarters · filed 2021-02-24 | $209.84M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $51.94M 10-K · filed 2020-02-26 | $101.47M derived: sum of 2 quarters · filed 2020-02-26 | $149.20M derived: sum of 3 quarters · filed 2020-02-26 | $194.03M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $49.53M 10-K · filed 2020-02-26 | $97.26M derived: sum of 2 quarters · filed 2020-02-26 | $142.09M 10-Q · filed 2019-10-31 | $183.70M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $47.73M 10-K · filed 2020-02-26 | $92.56M 10-Q · filed 2019-08-01 | $134.17M derived: sum of 3 quarters · filed 2020-02-26 | $170.75M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $44.83M 10-K · filed 2020-02-26 | $86.44M derived: sum of 2 quarters · filed 2020-02-26 | $123.02M derived: sum of 3 quarters · filed 2020-02-26 | $155.48M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $41.61M 10-K · filed 2019-03-01 | $78.19M derived: sum of 2 quarters · filed 2019-03-01 | $110.65M derived: sum of 3 quarters · filed 2019-03-01 | $141.24M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $36.58M 10-K · filed 2019-03-01 | $69.03M derived: sum of 2 quarters · filed 2019-03-01 | $99.62M 10-Q · filed 2018-11-01 | |||||
| 2017-06-30 | $32.45M 10-K · filed 2019-03-01 | $63.05M 10-Q · filed 2018-08-02 | ||||||
| 2017-03-31 | $30.59M 10-K · filed 2019-03-01 | |||||||
| 2016-12-31 | $104.54M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |